R.F.K. Jr. Wants to Overhaul the F.D.A. How Would Scientists Change It?news2024-12-22T10:00:41+00:00December 22nd, 2024|The New York Times|
Trial of Controversial Alzheimer’s Drug Halted After Disappointing Resultsnews2024-11-26T01:42:26+00:00November 26th, 2024|The New York Times|
What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trialsnews2024-10-23T14:19:56+00:00October 23rd, 2024|The New York Times|
Officials Cast Doubt on a Dementia Drug, but Human Trials Continuenews2024-10-02T19:41:40+00:00October 2nd, 2024|The New York Times|
Qué es la rapamicina y por qué se piensa que sirve para mantenerse jovennews2024-09-24T21:30:27+00:00September 24th, 2024|The New York Times|
Rapamycin and Anti-Aging: What to Knownews2024-09-24T15:26:30+00:00September 24th, 2024|The New York Times|
El ‘médico rural’ que transformó nuestra manera de ver la demencianews2024-09-14T09:03:22+00:00September 14th, 2024|The New York Times|
Francisco Lopera, the ‘Country Doctor’ Who Upended Our Understanding of Dementianews2024-09-11T14:07:34+00:00September 11th, 2024|The New York Times|
Executives Depart Cassava, Maker of Disputed Alzheimer’s Drugnews2024-07-18T22:21:49+00:00July 18th, 2024|The New York Times|
FDA Approves Donanemab, Eli Lilly’s New Drug for Early Alzheimer’snews2024-07-02T18:58:44+00:00July 2nd, 2024|The New York Times|
